Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887339 · ClinicalTrials.gov registry record · NA
Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project
A NA study, sponsored by Temple University.
- Completed
- Registry status
- NA
- Development phase
- 512
- Enrollment target
NCT02887339: Completed NA study, sponsored by Temple University.
NCT02887339 is a NA study that has completed, run by Temple University. The registered enrollment target is 512 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02887339, a NA study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- NA
- Development phase
- 512 participants
- Enrollment target
Study Summary
The Ethical, Legal and Social Issues Substudy in relation to the Genotype Tissue Expression Project (GTEx) aims to describe tissue requesters' approach to discussions about donation to GTEx and to assess the determinants of families' and patients' willingness to donate to GTEx. It also explores ethical issues such as privacy, risks, and release of incidental findings and recommend best practices for conducting authorizations and training requesters.
Primary Outcome
Number of family decision makers who choose to donate to GTEx
Interventions
- OTHER Control
- OTHER Training Website
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-12 |
| Phase | NA |
What the finished NCT02887339 record still lists
NCT02887339 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT02887339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02887339 about?
NCT02887339 is a clinical study titled "Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project". The Ethical, Legal and Social Issues Substudy in relation to the Genotype Tissue Expression Project (GTEx) aims to describe tissue requesters' approach to discussions about donation to GTEx and to assess the determinants of families' and patients' willingness to donate to GTEx. It also explores ethi...
What is the current status of trial NCT02887339?
This trial is currently completed. It is a NA study. The enrollment target is 512 participants. The study started on 2013-03. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02887339?
The interventions under investigation include: Control (OTHER), Training Website (OTHER).
Who is sponsoring clinical trial NCT02887339?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02887339's enrollment target sits among peer trials
512 192nd of 2000 higher than 1,809 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia